Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.